Ardelyx Inc. (Nasdaq: ARDX) reported positive results from a Phase 3 study of tenapanor to treat irritable bowel syndrome with constipation sending the stock price soaring $2.40 to close at $7.80.
Ardelyx reports positive study results
October 12, 2017 at 16:48 PM EDT
